Disease Severity
Disease Severity - Related Videos
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
0 Views •
Cited by 26 •
2013
Psoriasis is a chronic, immune-mediated inflammatory skin disease. The Goeckerman regimen, formulated for the treatment of psoriasis, consists of exposure to ultraviolet B (UVB) light and application of crude coal tar (CCT). The following protocol is for the administration of Goeckerman therapy for the treatment of moderate-to-severe psoriasis.
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
0 Views •
Cited by 4 •
2010
Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.
02:28
Measuring Psoriasis Severity at Home
0 Views •
2024
This paper details the creation of a Psoriasis Thickness Reference Card, enabling psoriasis patients to self-assess their psoriasis plaque thickness without the need for physician assistance. Additionally, the precision of self-assessment for psoriasis redness and scaliness by employing reference images depicting various skin tones is assessed.
10:00
A Contusion Model of Severe Spinal Cord Injury in Rats
0 Views •
Cited by 41 •
2013
A contusion model of severe spinal cord injury is described. Detailed pre-operative, operative and post-operative steps are described to obtain a consistent model.
12:03
Fertility Preservation in Patients with Severe Ovarian Dysfunction
0 Views •
Cited by 3 •
2021
We present details of laboratory procedures for drug-free in vitro activation (IVA) of ovarian follicles for patients with severe ovarian dysfunction. This method could increase the number of retrievable oocytes per ovarian hyperstimulation and benefit fertility preservation for those patients.
FAQs
Combining clinical scales with cognitive or motor performance and, when appropriate, neuroimaging, electrophysiology, or molecular biomarkers creates a broader picture of disease burden. Each modality captures a different aspect of the disorder, while their joint interpretation can relate observable symptoms and functional impairment to biological changes. This multidimensional approach supports more informative comparisons among individuals and across time.
Severity describes the extent of impairment or biological abnormality at a given assessment, whereas progression concerns how those features change over time. Repeated clinical scales and performance measures can track evolving symptoms and function, while imaging, electrophysiological, or molecular data may reveal corresponding neural changes. Separating these concepts helps researchers report current burden without confusing it with the rate or risk of future deterioration.
These measures add biological context to clinical observations. Neuroimaging can contribute evidence about changes in the nervous system, electrophysiology can provide another measure of neural activity, and molecular biomarkers can indicate disease-related biological changes. Their value is greatest when considered alongside standardized scales and cognitive or motor testing, because severity judgments then connect patient experience with measurable neural or molecular findings.
Clinical scales and performance tests address related but nonidentical dimensions. Standardized scales provide a structured way to record symptoms and functional impairment, whereas cognitive and motor tasks provide performance-based measures. Using both can show whether observed disease burden is reflected in measurable abilities, helping investigators select complementary outcomes for monitoring and comparison.
A practical workflow begins with selecting standardized clinical scales and performance measures suited to the disorder, then adding neuroimaging, electrophysiology, or molecular biomarkers when relevant. Investigators collect these measures consistently, compare results across individuals or visits, and examine relationships among symptoms, function, biological changes, and progression. The resulting profile supports classification, longitudinal monitoring, and evaluation of treatment response.
In clinical studies, severity measures help stratify participants so groups can be compared with greater clarity. They also provide outcomes for tracking whether symptoms, functional performance, or biological findings change during treatment. Repeated assessments can support interpretation of response over time and help relate study results to the underlying disease burden observed in participants.
In neuroscience, severity measures help connect patient outcomes with changes in neural circuits. Clinical scales and cognitive or motor performance describe what the individual experiences or can do, while imaging, electrophysiology, and molecular biomarkers add biological measurements. Examining these together can clarify how circuit-level changes relate to symptoms, impairment, progression, and treatment response.